NWU Institutional Repository

A call for improved reporting on serious adverse events in clinical trials

Loading...
Thumbnail Image

Date

Authors

Schutte, Aletta E.

Journal Title

Journal ISSN

Volume Title

Publisher

Wolters Kluwer

Abstract

Following SPRINT (Systolic Blood Pressure Intervention Trial) [1], several investigations including systematic reviews and meta-analyses confirmed that reducing SBP to levels below 140 mmHg markedly reduces the risk of cardiovascular disease and all-cause mortality. In a recent systematic review, Bundy et al. [2] included 42 trials (including 144 220 patients) and showed that randomized groups with a mean achieved SBP of 120–124 mmHg had a hazard ratio for major cardiovascular disease of 0.71 (95% confidence interval 0.60–0.83) compared with groups with a mean achieved SBP of 130–134 mmHg; a hazard ratio of 0.58 compared with those with an achieved SBP of 140–144 mmHg; and a hazard ratio of 0.36 compared with those with a mean achieved SBP of at least 160 mmHg. Similar findings were reported for all-cause mortality. These and other reports call for more intensive control of SBP among adults with hypertension

Description

Keywords

Citation

Schutte, A.E. 2019. A call for improved reporting on serious adverse events in clinical trials. Journal of hypertension, 37(11):2154-2155. [https://doi.org/10.1097/HJH.0000000000002194]

Endorsement

Review

Supplemented By

Referenced By